Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

chron.com - Molly Wilhelm - Pharma giant bets $2.3B on Houston with massive new campus
Pharma giant bets $2.3B on Houston with massive new campus
Chron

One of the nation's largest pharmaceutical companies has officially selected Houston for a massive $2.3 billion manufacturing campus. On Monday, Bristol Myers Squibb announced it had selected Generation Park in Houston for a new 'state-of-the-art…

rediff.com - Sohini Das - Indian Pharma Firms Maintain India Base, Focus on Complex US Products Amid Tariff Threat
Indian Pharma Firms Maintain India Base, Focus on Complex US Products Amid Tariff Threat
Rediff.com

Despite former US President Donald Trump's renewed threat of tariffs up to 200 per cent on imported generic drugs, Indian pharmaceutical companies are strategically maintaining India as their primary production base while making selective…

afr.com - Euan Black - Why big pharma hasn't invested in unapproved peptides
Why big pharma hasn't invested in unapproved peptides
Australian Financial Review

Doctors who prescribe unapproved peptides – and the patients who take them – often have a ready-made response for when someone mentions the lack of clinical trial data to support their much-loved injectables. “It's because big…

thehindu.com - The Hindu Bureau - Gland Pharma Q1 net surges 47% to ₹317 cr on higher revenue
Gland Pharma Q1 net surges 47% to ₹317 cr on higher revenue
The Hindu

Injectable-focussed generic drugmaker Gland Pharma reported consolidated net profit for June quarter rose 47% year-on-year (YoY) to ₹317 crore. It came on a 20% YoY increase in revenue from operations to ₹1,800.3 crore. On a…

thehindubusinessline.com - Gland Pharma net profit rises 47% to ₹317 crore in Q1
Gland Pharma net profit rises 47% to ₹317 crore in Q1
BusinessLine

Gland Pharma's consolidated net profit increased 47 per cent to ₹317 crore in the first quarter ended June 30, 2026, compared to ₹215 crore in the corresponding quarter of the previous financial year. The total revenue of the…

thehindubusinessline.com - AstraZeneca Pharma India Q1 profit drops to ₹37.93 crore
AstraZeneca Pharma India Q1 profit drops to ₹37.93 crore
BusinessLine

AstraZeneca Pharma India Ltd on Monday reported a 32 per cent decline in profit after tax at ₹37.93 crore in the June quarter, impacted by higher expenses. The company had posted a profit after tax of ₹55.83 crore in the corresponding…

pehub.com - Nina Lindholm - Spain a 'value destination' for mid-market investors; Wise Equity to acquire E-Pharma Trento
Spain a 'value destination' for mid-market investors; Wise Equity to acquire E-Pharma Trento
PE Hub

A verification email is on its way to you. Please check your spam or junk folder just in case. If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email:.

thehindubusinessline.com - Stocks to watch today: Signature Global, IndusInd Bank, pharma, railway and renewable energy stocks
Stocks to watch today: Signature Global, IndusInd Bank, pharma, railway and renewable energy stocks
BusinessLine

Signature Global has awarded construction contracts worth Rs 920 crore to KEC International Ltd (Rs 460 crore) and NCC (Rs 460 crore), for its premium housing project ‘Sarvam at DXP Estate', located in Sector 37D, Dwarka Expressway…

marketbeat.com - Royal Bank of Canada Purchases 23,479 Shares of Royalty Pharma PLC $RPRX
Royal Bank of Canada Purchases 23,479 Shares of Royalty Pharma PLC $RPRX
MarketBeat

Royal Bank of Canada boosted its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 15.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned…

marketbeat.com - Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright
Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright
MarketBeat

3 Bullish Biotech Stocks With Explosive Growth Trends Urogen Pharma (NASDAQ:URGN - Free Report) - Research analysts at HC Wainwright lifted their Q3 2026 EPS estimates for shares of Urogen Pharma in a research note issued on Thursday, August 6th.

marketbeat.com - Athira Pharma, Inc. (NASDAQ:LONA) Receives Consensus Recommendation of 'Moderate Buy' from Analysts
Athira Pharma, Inc. (NASDAQ:LONA) Receives Consensus Recommendation of 'Moderate Buy' from Analysts
MarketBeat

Athira Pharma, Inc. (NASDAQ:LONA - Get Free Report) has been given an average recommendation of 'Moderate Buy' by the six research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the…

scmp.com - Alice Li - China's drug firms set to compete on the world stage, analysts say
China's drug firms set to compete on the world stage, analysts say
South China Morning Post

Thanks to an efficiency edge that transcends simple cost advantages, China is set to see the emergence of a home-grown drug giant capable of competing with global players in a decade, analysts say. “For the past three decades, there was only…

seekingalpha.com - Albert Anthony - Ryman Hospitality Properties Sings A Bullish Tune After Q2 Results Show Continued Growth
Ryman Hospitality Properties Sings A Bullish Tune After Q2 Results Show Continued Growth
Seeking Alpha

Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…

prweb.com - Molecular Devices - Molecular Devices and HeartBeat.bio Help Researchers Identify Cardiac Safety Risks Earlier with New Human Cardiac Organoid Solution
Molecular Devices and HeartBeat.bio Help Researchers Identify Cardiac Safety Risks Earlier with New Human Cardiac Organoid Solution
PRWeb

'Researchers are under increasing pressure to make faster, more informed decisions while reducing risk throughout the drug development process,' said Mary Duseau, President of Molecular Devices. 'Together with HeartBeat.bio, we're helping make…

newswire.ca - Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States
CNW

MUMBAI, India and NAPLES, Fla., Aug. 10, 2026 /CNW/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the U.S. Food and Drug…

Receive a Daily briefing on Pharma Industry News

Get Started